193 related articles for article (PubMed ID: 38636809)
1. Incretin hormones, obesity and gut microbiota.
Angelini G; Russo S; Mingrone G
Peptides; 2024 Aug; 178():171216. PubMed ID: 38636809
[TBL] [Abstract][Full Text] [Related]
2. Incretins in obesity and diabetes.
Chia CW; Egan JM
Ann N Y Acad Sci; 2020 Feb; 1461(1):104-126. PubMed ID: 31392745
[TBL] [Abstract][Full Text] [Related]
3. Cellular mechanisms of incretin hormone secretion.
Santos-Hernández M; Reimann F; Gribble FM
J Mol Endocrinol; 2024 May; 72(4):. PubMed ID: 38240302
[TBL] [Abstract][Full Text] [Related]
4. Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity.
Opinto G; Natalicchio A; Marchetti P
Arch Physiol Biochem; 2013 Oct; 119(4):170-8. PubMed ID: 23859800
[TBL] [Abstract][Full Text] [Related]
5. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
6. The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.
João AL; Reis F; Fernandes R
Obes Rev; 2016 Jul; 17(7):553-72. PubMed ID: 27125902
[TBL] [Abstract][Full Text] [Related]
7. Incretin hormones: Their role in health and disease.
Nauck MA; Meier JJ
Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
[TBL] [Abstract][Full Text] [Related]
8. Diabetes remission after bariatric surgery: is it just the incretins?
Laferrère B
Int J Obes (Lond); 2011 Sep; 35 Suppl 3(0 3):S22-5. PubMed ID: 21912382
[TBL] [Abstract][Full Text] [Related]
9. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
[TBL] [Abstract][Full Text] [Related]
10. Physiological mechanisms of action of incretin and insulin in regulating skeletal muscle metabolism.
Abdulla H; Phillips B; Smith K; Wilkinson D; Atherton PJ; Idris I
Curr Diabetes Rev; 2014; 10(5):327-35. PubMed ID: 25323297
[TBL] [Abstract][Full Text] [Related]
11. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.
Yabe D; Seino Y
Prog Biophys Mol Biol; 2011 Nov; 107(2):248-56. PubMed ID: 21820006
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide stimulate release of substance P from TRPV1- and TRPA1-expressing sensory nerves.
Mayer F; Gunawan AL; Tso P; Aponte GW
Am J Physiol Gastrointest Liver Physiol; 2020 Jul; 319(1):G23-G35. PubMed ID: 32421358
[TBL] [Abstract][Full Text] [Related]
13. Incretin hormones and type 2 diabetes.
Nauck MA; Müller TD
Diabetologia; 2023 Oct; 66(10):1780-1795. PubMed ID: 37430117
[TBL] [Abstract][Full Text] [Related]
14. Novel extrapancreatic effects of incretin.
Yamada Y; Tsukiyama K; Sato T; Shimizu T; Fujita H; Narita T
J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):76-9. PubMed ID: 27186360
[TBL] [Abstract][Full Text] [Related]
15. [Incretin hormones in the treatment of type 2 diabetes. Part I: influence of insulinotropic gut-derived hormones (incretins) on glucose metabolism].
Matuszek B; Lenart-Lipińska M; Nowakowski A
Endokrynol Pol; 2007; 58(6):522-8. PubMed ID: 18205109
[TBL] [Abstract][Full Text] [Related]
16. Roles of glucose-dependent insulinotropic polypeptide in diet-induced obesity.
Seino Y; Yamazaki Y
J Diabetes Investig; 2022 Jul; 13(7):1122-1128. PubMed ID: 35452190
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Type 2 Diabetes and Obesity on the Basis of the Incretin System: The 2021 Banting Medal for Scientific Achievement Award Lecture.
Holst JJ
Diabetes; 2021 Nov; 70(11):2468-2475. PubMed ID: 34711671
[TBL] [Abstract][Full Text] [Related]
18. GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists.
Holst JJ; Rosenkilde MM
J Clin Endocrinol Metab; 2020 Aug; 105(8):e2710-6. PubMed ID: 32459834
[TBL] [Abstract][Full Text] [Related]
19. EndoBarrier gastrointestinal liner. Delineation of underlying mechanisms and clinical effects.
Rohde U
Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808040
[TBL] [Abstract][Full Text] [Related]
20. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.
Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M
Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
